ABL002
Total Payments
$11.5M
Transactions
105
Doctors
36
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.3M | 34 | 19 |
| 2019 | $3.5M | 36 | 15 |
| 2018 | $1.6M | 29 | 14 |
| 2017 | $4.1M | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.3M | 35 | 98.9% |
| Consulting Fee | $124,198 | 44 | 1.1% |
| Travel and Lodging | $2,557 | 10 | 0.0% |
| Food and Beverage | $1,096 | 15 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $719.80 | 1 | 0.0% |
Payments by Type
Research
$11.3M
35 transactions
General
$128,570
70 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I MULTICENTER OPEN LABEL STUDY OF ORAL ABL001 IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA OR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTICLEUKEMIA | Novartis Pharmaceuticals Corporation | $11.3M | 0 |
| A BIOLOGY STUDY OF THE MECHANISMS OF RESISTANCE TO TARGETED THERAPIES PLEASE NOTE THAT THIS IS A NON TREATMENT PROTOCOL | Novartis Pharmaceuticals Corporation | $22,500 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,885 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $672.00 | 4 |
Top Doctors Receiving Payments for ABL002 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Houston, TX | $1,880 | 1 |
| , MD | Hematology & Oncology | Kettering, OH | $1,440 | 1 |
| Nobuko Hijiya | — | Memphis, TN | $1,395 | 2 |
| , MD | Hematology | Chicago, IL | $628.33 | 1 |
| , MD | Hematology & Oncology | Portland, OR | $628.33 | 1 |
| , MD | Internal Medicine | Duarte, CA | $391.53 | 3 |
| , M.D | Hematology & Oncology | Houston, TX | $295.97 | 2 |
| , MD | Medical Oncology | Baltimore, MD | $46.55 | 1 |
| , MD | Hematology & Oncology | Buffalo, NY | $46.55 | 1 |
| , MD | Medical Oncology | Seattle, WA | $46.55 | 1 |
| , M.D | Forensic Psychiatry | Northfield, OH | $46.55 | 1 |
| , MD | Medical Oncology | Boston, MA | $46.55 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $11.5M
- Total Doctors 36
- Transactions 105
About ABL002
ABL002 is a drug associated with $11.5M in payments to 36 healthcare providers, recorded across 105 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $2.3M was paid across 34 transactions to 19 doctors.
The most common payment nature for ABL002 is "Unspecified" ($11.3M, 98.9% of total).
ABL002 is associated with 4 research studies, including "A PHASE I MULTICENTER OPEN LABEL STUDY OF ORAL ABL001 IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA OR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTICLEUKEMIA" ($11.3M).